Advanced in Graft Versus Host Disease (GvHD)

Dr. Vinod Prasad

Pediatrics
Duke Children's Hospital & Health Center
2301 Erwin Rd, 
Durham, NC 
Offers Telehealth
Advanced in Graft Versus Host Disease (GvHD)
Duke Children's Hospital & Health Center
2301 Erwin Rd, 
Durham, NC 
OverviewInsuranceLocationsClinical Research

Overview

Vinod Prasad is a Pediatrics provider in Durham, North Carolina. Dr. Prasad is rated as an Advanced provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). His top areas of expertise are Graft Versus Host Disease (GvHD), Autoimmune Hemolytic Anemia, Pure Red Cell Aplasia, Non-Langerhans-Cell Histiocytosis, and Bone Marrow Transplant.

His clinical research consists of co-authoring 49 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 18 articles in the study of Graft Versus Host Disease (GvHD).

Specialties
Pediatrics
Licenses
Pediatric Critical Care Medicine in NC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Piedmont
  • HMO
  • POS
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

Duke Children's Hospital & Health Center
2301 Erwin Rd, Durham, NC 27705
Other Locations
Office
2100 Erwin Rd, Durham, NC 27705

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
Enrollment Status: Active_not_recruiting
Publish Date: February 03, 2026
Intervention Type: Drug, Device
Study Drug: Busulfan
Study Phase: Phase 2
Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease
Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2026
Intervention Type: Drug, Biological
Study Drugs: Alemtuzumab, Fludarabine, Cyclosporine, Mycophenolate Mofetil
Study Phase: Phase 2
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Enrollment Status: No_longer_available
Publish Date: March 14, 2022
Intervention Type: Drug
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Enrollment Status: Terminated
Publish Date: January 25, 2021
Intervention Type: Other, Drug
Study Phase: Phase 2
A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy
A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy
Enrollment Status: Terminated
Publish Date: May 21, 2020
Intervention Type: Genetic
View 4 Less Clinical Trials

49 Total Publications

Umbilical Cord Blood Transplantation Provides an Alternative for Patients With Chronic Granulomatous Disease Lacking HLA-Matched Donors: A PIDTC Report.
Umbilical Cord Blood Transplantation Provides an Alternative for Patients With Chronic Granulomatous Disease Lacking HLA-Matched Donors: A PIDTC Report.
Journal: Transplantation and cellular therapy
Published: March 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Prasad's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile